SLC15A4-TASL complex emerges as crucial therapeutic target for lupus by regulating TLR-induced IFN-alpha signaling

Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by systemic inflammation and multi-organ involvement, driven significantly by type I interferon (IFN) responses. Toll-like receptors (TLRs), particularly TLR7, TLR8, and TLR9, play a central role in triggering these IFN responses in immune cells like B cells and plasmacytoid dendritic cells (pDCs). Current treatments for SLE often involve broad immunosuppression, which can have significant side effects. Understanding specific molecular drivers, like the TLR-IFN-alpha pathway, is crucial for developing more targeted and effective therapies.

This review synthesizes current knowledge on the SLC15A4:TASL complex, detailing its structural interaction, established role in SLE pathogenesis, and its function in facilitating endo-lysosomal TLR7, TLR8, and TLR9 signaling. It surveys existing small molecule inhibitors that target SLC15A4 to disrupt this pathway, along with available tools for future drug discovery efforts. The authors compiled evidence regarding SLC15A4's traditional proton-dependent histidine and peptide transporter activity versus its more recently identified scaffolding role in immune signaling.

The review highlights that SLC15A4, traditionally viewed as a peptide transporter, primarily functions as a scaffolding protein through its interaction with a newly identified signal transducer, TASL. This complex is essential for mediating TLR7, TLR8, and TLR9 induced IRF5 activation, a critical pathway driving IFN-alpha production in B cells and pDCs, which is central to lupus pathogenesis. > Inhibition of SLC15A4, either genetically or via small molecule binders, effectively suppresses TLR7, TLR8, or TLR9 signaling, thereby reducing pro-inflammatory cytokine release. The authors detail several small molecule SLC15A4 binders that have demonstrated inhibitory effects on these TLR pathways. The review also discusses the ongoing debate regarding the extent of SLC15A4's transporter activity versus its scaffolding function, concluding that its scaffolding role with TASL is paramount for TLR signaling in the context of SLE.